Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Vor Biopharma reports Q1 EPS (67c), consensus (62c) » 17:06
05/06/21
05/06
17:06
05/06/21
17:06
VOR

Vor Biopharma

$23.51 /

-3.245 (-12.13%)

Vor finished the first…

Vor finished the first quarter of 2021 with $262.6 million in cash and cash equivalents, compared with $48.5 million as of December 31, 2020. Cash and cash equivalents on March 31, 2021 includes the $186.3 million in net proceeds from the Company's IPO completed in February 2021 as well as $45.4 million in net proceeds from the completion of its Series B preferred stock financing in January 2021."The Vor team remains focused on delivering upon multiple clinical and operational milestones," said Robert Ang, MBBS, MBA, Vor's President and Chief Executive Officer. "We have established a strong foundation to generate several important catalysts over the next 12 to 24 months which will demonstrate the potential of Vor's novel platform. With respect to our lead clinical program, VOR33 in patients suffering from acute myeloid leukemia, we remain on track to enroll the first patient in our Phase 1/2a trial in the second quarter of 2021."

ShowHide Related Items >><<
VOR Vor Biopharma
$23.51 /

-3.245 (-12.13%)

VOR Vor Biopharma
$23.51 /

-3.245 (-12.13%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
  • 05
    Feb
VOR Vor Biopharma
$23.51 /

-3.245 (-12.13%)

Over a week ago
Conference/Events
Vor Biopharma management to meet virtually with B. Riley » 04:55
04/23/21
04/23
04:55
04/23/21
04:55
VOR

Vor Biopharma

$29.50 /

+2 (+7.27%)

Virtual Meeting to be…

Virtual Meeting to be held on April 23 hosted by B. Riley.

ShowHide Related Items >><<
VOR Vor Biopharma
$29.50 /

+2 (+7.27%)

VOR Vor Biopharma
$29.50 /

+2 (+7.27%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
  • 05
    Feb
VOR Vor Biopharma
$29.50 /

+2 (+7.27%)

Conference/Events
Vor Biopharma management to meet virtually with B. Riley » 10:11
04/22/21
04/22
10:11
04/22/21
10:11
VOR

Vor Biopharma

$26.98 /

-0.52 (-1.89%)

Virtual Meeting to be…

Virtual Meeting to be held on April 23 hosted by B. Riley.

ShowHide Related Items >><<
VOR Vor Biopharma
$26.98 /

-0.52 (-1.89%)

VOR Vor Biopharma
$26.98 /

-0.52 (-1.89%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
  • 05
    Feb
VOR Vor Biopharma
$26.98 /

-0.52 (-1.89%)

Over a month ago
Initiation
Vor Biopharma initiated with a Buy at B. Riley Securities » 05:50
03/25/21
03/25
05:50
03/25/21
05:50
VOR

Vor Biopharma

$38.62 /

-3.66 (-8.66%)

B. Riley Securities…

B. Riley Securities analyst Justin Walsh last night initiated coverage of Vor Biopharma with a Buy rating and $60 price target, which represents a potential 48% increase from current levels. The analyst believes the company's lead asset, VOR33, "could dramatically change" the acute myeloid leukemia treatment landscape, "potentially improving and prolonging thousands of patients' lives and generating billions of dollars of sales across major markets." He also expect the Vor's companion therapeutic, VCAR33, to provide "considerable" clinical and commercial synergies, in turn enabling VOR33 to optimize its potential.

ShowHide Related Items >><<
VOR Vor Biopharma
$38.62 /

-3.66 (-8.66%)

VOR Vor Biopharma
$38.62 /

-3.66 (-8.66%)

03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
02/10/21 Piper Sandler
PureTech Health price target raised to $76 from $66 at Piper Sandler
  • 05
    Feb
VOR Vor Biopharma
$38.62 /

-3.66 (-8.66%)

Initiation
Vor Biopharma initiated with an Outperform at Evercore ISI » 16:47
03/02/21
03/02
16:47
03/02/21
16:47
VOR

Vor Biopharma

$42.46 /

-5.54 (-11.54%)

Evercore ISI analyst Umer…

Evercore ISI analyst Umer Raffat initiated coverage of Vor Biopharma with an Outperform rating and $48 price target. Raffat said that Vor's transplant program is "just getting started," though it's already "driving a lot of interest" due to the company's "innovative" application of existing technology.

ShowHide Related Items >><<
VOR Vor Biopharma
$42.46 /

-5.54 (-11.54%)

VOR Vor Biopharma
$42.46 /

-5.54 (-11.54%)

03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
02/10/21 Piper Sandler
PureTech Health price target raised to $76 from $66 at Piper Sandler
  • 05
    Feb
VOR Vor Biopharma
$42.46 /

-5.54 (-11.54%)

Initiation
Vor Biopharma initiated with a Buy at Stifel » 07:00
03/02/21
03/02
07:00
03/02/21
07:00
VOR

Vor Biopharma

$48.00 /

+3.06 (+6.81%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey initiated coverage of Vor Biopharma with a Buy rating and $58 price target, stating that the company's technology platform represents a unique and differentiated approach to improving outcomes in difficult-to-treat hematological malignancy patients. Willey expects ongoing Phase 1/2 trials to establish clinical proof-of-concept for both VOR33 and VCAR33 and believes the subsequent integration into the VOR33/VCAR33 Treatment System will greatly enhance the value proposition of an allogeneic hematopoietic stem cell transplant, the analyst tells investors.

ShowHide Related Items >><<
VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
02/10/21 Piper Sandler
PureTech Health price target raised to $76 from $66 at Piper Sandler
  • 05
    Feb
VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

Initiation
Vor Biopharma initiated with a Sell at Goldman Sachs » 04:59
03/02/21
03/02
04:59
03/02/21
04:59
VOR

Vor Biopharma

$48.00 /

+3.06 (+6.81%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh initiated coverage of Vor Biopharma with a Sell rating and $19 price target. The analyst looks forward to Vor's "innovative approaches" to improving stem cell transplantation outcomes when treating blood cancers. However, with the shares shares up 160% since the initial public offering, he sees the risk/reward as "skewed to the downside at current levels."

ShowHide Related Items >><<
VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

02/10/21 Piper Sandler
PureTech Health price target raised to $76 from $66 at Piper Sandler
  • 05
    Feb
VOR Vor Biopharma
$48.00 /

+3.06 (+6.81%)

Recommendations
PureTech Health price target raised to $76 from $66 at Piper Sandler » 09:39
02/10/21
02/10
09:39
02/10/21
09:39
PRTC

PureTech Health

$57.00 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$114.79 /

-10.21 (-8.17%)

, VOR

Vor Biopharma

$43.00 /

+0.17 (+0.40%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on PureTech Health (PRTC) to $76 from $66 and reiterates an Overweight rating on the shares. Puretech sold 1M Karuna Therapeutics (KRTX) shares for $118M and still holds 2.4M shares or about 9% of Karuna, Tenthoff tells investors in a research note. Separately, Vor Biopharma (VOR) completed a successful initial public offering and PureTech retains 3.2M Vor shares, the analyst adds. These two deals account for the target raise.

ShowHide Related Items >><<
VOR Vor Biopharma
$43.00 /

+0.17 (+0.40%)

PRTC PureTech Health
$57.00 /

+ (+0.00%)

KRTX Karuna Therapeutics
$114.79 /

-10.21 (-8.17%)

PRTC PureTech Health
$57.00 /

+ (+0.00%)

01/15/21 SVB Leerink
PureTech Health initiated with an Outperform at SVB Leerink
11/17/20 Piper Sandler
PureTech Health initiated with an Overweight at Piper Sandler
KRTX Karuna Therapeutics
$114.79 /

-10.21 (-8.17%)

02/09/21
Fly Intel: Top five analyst initiations
02/09/21 RBC Capital
Karuna Therapeutics initiated with an Outperform at RBC Capital
11/19/20 Maxim
Karuna Therapeutics initiated with a Buy at Maxim
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
VOR Vor Biopharma
$43.00 /

+0.17 (+0.40%)

KRTX Karuna Therapeutics
$114.79 /

-10.21 (-8.17%)

  • 05
    Feb
VOR Vor Biopharma
$43.00 /

+0.17 (+0.40%)

KRTX Karuna Therapeutics
$114.79 /

-10.21 (-8.17%)

Hot Stocks
Vor Biopharma Chairman Parmar purchased $10M in company shares » 17:20
02/09/21
02/09
17:20
02/09/21
17:20
VOR

Vor Biopharma

$43.00 /

+0.17 (+0.40%)

Vor Biopharma Chairman…

Vor Biopharma Chairman Kush Parmar disclosed in a filing that he had purchased 555,555 shares of company stock on February 9 at $18.00 per share for a total transaction amount of $9,999,990.

ShowHide Related Items >><<
  • 05
    Feb
VOR Vor Biopharma
$43.00 /

+0.17 (+0.40%)

On The Fly
Opening Day: Sana raises largest-ever IPO for preclinical biotech » 09:27
02/07/21
02/07
09:27
02/07/21
09:27
NXU

Novus Capital Corporation II

$0.00 /

+ (+0.00%)

, CENHU

Centricus Acquisition

$10.49 /

+0.09 (+0.87%)

, LHDX

Lucira Health

$25.00 /

+1.83 (+7.90%)

, CNEY

CN Energy

$5.35 /

-3.21 (-37.50%)

, VOR

Vor Biopharma

$36.20 /

-5.81 (-13.83%)

, TERN

Terns Pharmaceuticals

$17.94 /

+0.99 (+5.84%)

, EVAX

Evaxion Biotech

$9.74 /

-0.25 (-2.50%)

, PHVS

Pharvaris

$29.00 /

+3.5 (+13.73%)

, ANGN

Angion Biomedica

$16.68 /

-1.32 (-7.33%)

, BOLT

Bolt Biotherapeutics

$32.30 /

+5.85 (+22.12%)

, IMCR

Immunocore

$44.00 /

+4 (+10.00%)

, SANA

Sana Biotechnology

$39.03 /

+4.03 (+11.51%)

, LABP

Landos Biopharma

$11.06 /

-1.2 (-9.79%)

, SNSE

Sensei Biotherapeutics

$22.23 /

+3.21 (+16.88%)

, ATC

Atotech

$19.11 /

-0.105 (-0.55%)

, ONTF

On24

$69.60 /

+1.66 (+2.44%)

, TOT

Total

$42.28 /

+0.16 (+0.38%)

, TIXT

Telus International

$31.61 /

+0.94 (+3.06%)

, TU

Telus

$21.14 /

+0.28 (+1.34%)

, JOFF

JOFF Fintech Acquisition

$0.00 /

+ (+0.00%)

, FWAA

Fifth Wall Acquisition Corp. I

$11.25 /

+0.01 (+0.09%)

, TBCP

Thunder Bridge Capital Partners III

$0.00 /

+ (+0.00%)

, RMGC

RMG Acquisition Corp. III

$0.00 /

+ (+0.00%)

, DCRN

Decarbonization Plus Acquisition Corp. II

$0.00 /

+ (+0.00%)

, ASAX

Astrea Acquisition

$0.00 /

+ (+0.00%)

, ITQR

Itiquira Acquisition

$0.00 /

+ (+0.00%)

, ACII

Atlas Crest Investment Corp. II

$0.00 /

+ (+0.00%)

, GHAC

Gaming & Hospitality Acquisition

$0.00 /

+ (+0.00%)

, MDH

MDH Acquisition

$0.00 /

+ (+0.00%)

, AAC

Ares Acquisition

$0.00 /

+ (+0.00%)

, RBLX

Roblox

$0.00 /

+ (+0.00%)

, BMBL

Bumble

$0.00 /

+ (+0.00%)

, COIN

Coinbase

$0.00 /

+ (+0.00%)

, HOMS

Caliber Home Loans

$0.00 /

+ (+0.00%)

, PHAR

Pharming

$14.19 /

-0.31 (-2.14%)

, LDI

LoanDepot

$0.00 /

+ (+0.00%)

, APR

Apria

$0.00 /

+ (+0.00%)

Sana Biotechnology raised…

ShowHide Related Items >><<
TU Telus
$21.14 /

+0.28 (+1.34%)

TOT Total
$42.28 /

+0.16 (+0.38%)

RBLX Roblox
$0.00 /

+ (+0.00%)

LABP Landos Biopharma
$11.06 /

-1.2 (-9.79%)

COIN Coinbase
$0.00 /

+ (+0.00%)

NXU Novus Capital Corporation II
$0.00 /

+ (+0.00%)

CENHU Centricus Acquisition
$10.49 /

+0.09 (+0.87%)

LHDX Lucira Health
$25.00 /

+1.83 (+7.90%)

CNEY CN Energy
$5.35 /

-3.21 (-37.50%)

VOR Vor Biopharma
$36.20 /

-5.81 (-13.83%)

TERN Terns Pharmaceuticals
$17.94 /

+0.99 (+5.84%)

EVAX Evaxion Biotech
$9.74 /

-0.25 (-2.50%)

PHVS Pharvaris
$29.00 /

+3.5 (+13.73%)

ANGN Angion Biomedica
$16.68 /

-1.32 (-7.33%)

BOLT Bolt Biotherapeutics
$32.30 /

+5.85 (+22.12%)

IMCR Immunocore
$44.00 /

+4 (+10.00%)

SANA Sana Biotechnology
$39.03 /

+4.03 (+11.51%)

LABP Landos Biopharma
$11.06 /

-1.2 (-9.79%)

SNSE Sensei Biotherapeutics
$22.23 /

+3.21 (+16.88%)

ATC Atotech
$19.11 /

-0.105 (-0.55%)

ONTF On24
$69.60 /

+1.66 (+2.44%)

TOT Total
$42.28 /

+0.16 (+0.38%)

01/21/21 Jefferies
Total initiated with a Buy at Jefferies
01/19/21
Fly Intel: Top five analyst downgrades
01/19/21 Cowen
Cowen downgrades Total to Market Perform, In line performance seen
01/19/21 Cowen
Total downgraded to Market Perform from Outperform at Cowen
TIXT Telus International
$31.61 /

+0.94 (+3.06%)

TU Telus
$21.14 /

+0.28 (+1.34%)

02/05/21 CIBC
Telus price target raised to C$28 from C$26 at CIBC
01/22/21 JPMorgan
Telus price target raised to C$27 from C$25 at JPMorgan
01/08/21 National Bank
Telus price target raised to C$28 from C$27 at National Bank
01/08/21 TD Securities
Telus price target raised to C$30 from C$29 at TD Securities
JOFF JOFF Fintech Acquisition
$0.00 /

+ (+0.00%)

FWAA Fifth Wall Acquisition Corp. I
$11.25 /

+0.01 (+0.09%)

TBCP Thunder Bridge Capital Partners III
$0.00 /

+ (+0.00%)

RMGC RMG Acquisition Corp. III
$0.00 /

+ (+0.00%)

DCRN Decarbonization Plus Acquisition Corp. II
$0.00 /

+ (+0.00%)

ASAX Astrea Acquisition
$0.00 /

+ (+0.00%)

ITQR Itiquira Acquisition
$0.00 /

+ (+0.00%)

ACII Atlas Crest Investment Corp. II
$0.00 /

+ (+0.00%)

GHAC Gaming & Hospitality Acquisition
$0.00 /

+ (+0.00%)

MDH MDH Acquisition
$0.00 /

+ (+0.00%)

AAC Ares Acquisition
$0.00 /

+ (+0.00%)

RBLX Roblox
$0.00 /

+ (+0.00%)

BMBL Bumble
$0.00 /

+ (+0.00%)

COIN Coinbase
$0.00 /

+ (+0.00%)

HOMS Caliber Home Loans
$0.00 /

+ (+0.00%)

PHAR Pharming
$14.19 /

-0.31 (-2.14%)

LDI LoanDepot
$0.00 /

+ (+0.00%)

APR Apria
$0.00 /

+ (+0.00%)

TU Telus
$21.14 /

+0.28 (+1.34%)

  • 05
    Feb
  • 11
    Feb
  • 11
    Feb
  • 05
    Feb
  • 05
    Feb
  • 05
    Feb
  • 05
    Feb
  • 05
    Feb
  • 05
    Feb
  • 05
    Feb
  • 04
    Feb
  • 04
    Feb
  • 04
    Feb
  • 03
    Feb
  • 11
    Feb
  • 03
    Feb
  • 04
    Feb
  • 05
    Feb
  • 29
    Oct
TOT Total
$42.28 /

+0.16 (+0.38%)

RBLX Roblox
$0.00 /

+ (+0.00%)

COIN Coinbase
$0.00 /

+ (+0.00%)

TU Telus
$21.14 /

+0.28 (+1.34%)

RBLX Roblox
$0.00 /

+ (+0.00%)

HOMS Caliber Home Loans
$0.00 /

+ (+0.00%)

COIN Coinbase
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.